 |
|
Largest study of unrelated bone marrow transplantation for leukemia serves as benchmark
August 03, 2005Multi-institutional study addresses critical GVHD complication
Together with 16 other institutions in the United States, University of Minnesota researchers led the largest study to date in patients with leukemia and related disorders undergoing bone marrow transplantation from unrelated donors. The study was designed to determine whether one of two general approaches to prevent graft-versus-host-disease (GVHD), a potentially lethal complication, might result in improved survival.
While the trial demonstrated similar survival rates, the study was the most comprehensive to date, evaluating various clinical outcomes, resource utilization, costs, and health quality of life. The study, published in the Aug. 3, 2005 online issue of The Lancet, will likely serve as the benchmark for all future studies in this patient population.
Graft-versus-host-disease is a common complication after bone marrow transplantation in which the immune cells from the donated marrow attack the body of the patient who received the transplant. Severity ranges from mild to life threatening, and the disease and its treatment can have a profound effect on quality of life.
The two primary strategies for preventing GVHD, the removal of T-cells (the cell that causes GVHD) and immunosuppressive drug therapy (suppression of T-cell function), were studied in this trial. While the primary aim of the study was to demonstrate whether one approach might be better than the other in terms of disease-free survival three years after transplantation, the study also systematically compared the incidence of various complications (GVHD, graft failure, therapy-related side effects, disease recurrence) as well as utilization of blood products, nutritional supplementation, number of admissions to the hospital and intensive care unit, hospital costs, and health quality of life.
"While the T-cell depletion approach was very effective in reducing the risk of GVHD, a higher risk of viral infection in general and higher risk of disease recurrence specifically in patients with chronic myelogenous leukemia, eliminated the potential benefit of reduced GVHD," ," said John E. Wagner, M.D., professor of pediatrics and scientific director of clinical research, Blood and Marrow Transplantation Program and Stem Cell Institute, and lead author of the study. "Overall, we observed no differences in survival at three years and no appreciable differences in cost or quality of life."
These results counter what investigators might have guessed and reflect the critical importance of performing large randomized trials. "Prior to this study, colleagues promoting T-cell depletion, like myself, predicted that T-cell depletion would have offered a better chance of survival," Wagner said. "What is abundantly clear is that T-cell depletion and GVHD prevention is only one step in figuring out how to improve upon the chance of cure in unrelated marrow transplant patients. The next hurdle is to find ways to fix the crippled immune system."
Despite the lack of evidence that one approach was better than the other, "the results clearly point out the limitations of bone marrow transplants,\\\
University of Minnesota
The two primary strategies for preventing GVHD, the removal of T-cells (the cell that causes GVHD) and immunosuppressive drug therapy (suppression of T-cell function), were studied in this trial. While the primary aim of the study was to demonstrate whether one approach might be better than the other in terms of disease-free survival three years after transplantation, the study also systematically compared the incidence of various complications (GVHD, graft failure, therapy-related side effects, disease recurrence) as well as utilization of blood products, nutritional supplementation, number of admissions to the hospital and intensive care unit, hospital costs, and health quality of life.
"While the T-cell depletion approach was very effective in reducing the risk of GVHD, a higher risk of viral infection in general and higher risk of disease recurrence specifically in patients with chronic myelogenous leukemia, eliminated the potential benefit of reduced GVHD," ," said John E. Wagner, M.D., professor of pediatrics and scientific director of clinical research, Blood and Marrow Transplantation Program and Stem Cell Institute, and lead author of the study. "Overall, we observed no differences in survival at three years and no appreciable differences in cost or quality of life."
These results counter what investigators might have guessed and reflect the critical importance of performing large randomized trials. "Prior to this study, colleagues promoting T-cell depletion, like myself, predicted that T-cell depletion would have offered a better chance of survival," Wagner said. "What is abundantly clear is that T-cell depletion and GVHD prevention is only one step in figuring out how to improve upon the chance of cure in unrelated marrow transplant patients. The next hurdle is to find ways to fix the crippled immune system."
Despite the lack of evidence that one approach was better than the other, "the results clearly point out the limitations of bone marrow transplants,\\\
University of Minnesota
Bone Marrow Transplantation Current Events and Bone Marrow Transplantation News RSSGene mismatch influences success of bone marrow transplants
A commonly inherited gene deletion can increase the likelihood of immune complications following bone marrow transplantation, an international team of researchers reports in the November 22 advance online issue of Nature Genetics.
U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.
Scientists successfully reprogram blood cells
Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme -preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler's syndrome.
Turning back the clock: Fasting prolongs reproductive life span
Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone.
Potential risk identified in transfusions of platelets before bone marrow transplant
Research on blood transfusions points to a potential risk of transfusing donated platelets, especially to patients with bone marrow failure syndromes who are subsequently candidates for bone marrow transplantation.
NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped a clinical trial testing a drug treatment for pulmonary hypertension in adults with sickle cell disease nearly one year early due to safety concerns.
What do blood stem cells need to grow? Blood flow
Blood stem cells literally go with the flow, according to a new report published as an immediate early publication in the journal Cell, a Cell Press journal, on May 13th.
Study Finds Blood Cells Can Be Reprogrammed to Act as Embryonic Stem Cells
In a recent study, U.S. researchers have reprogrammed cells found in circulating blood into cells that are molecularly and functionally indistinguishable from embryonic stem cells, a revolutionary achievement that provides a readily accessible source of stem cells and an alternative to harvesting embryonic stem cells.
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment. Just as important, knowing which of a patient's cancer-causing genetic lesions are contributing to drug resistance might help doctors redesign therapy for maximum benefit.
Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases
An experimental procedure that dramatically strengthens stem cells' ability to regenerate damaged tissue could offer new hope to sufferers of muscle-wasting diseases such as myopathy and muscular dystrophy, according to researchers from the University of New South Wales (UNSW).
More Bone Marrow Transplantation Current Events and Bone Marrow Transplantation News Articles
 |
Manual of Stem Cell and Bone Marrow Transplantation (Cambridge Medicine) by Joseph H. Antin MD (Author), Deborah S. Yolin (Author) Over the past 35 years, stem cell and bone marrow transplantation have evolved from experimental therapies to well-established and widely used treatments for a variety of malignant and nonmalignant conditions. This is a practical pocket manual for all members of the stem cell and bone marrow transplant team, based on a popular in-house handbook used at the Dana-Farber Cancer Institute. The manual covers all aspects of the transplantation process, from stem cell processing through management of transplant-related complications. Evaluation and counseling of patients and donors, preventative care, and conditioning regimens are also covered, making this an ideal resource for nurses as well. The text is handily arranged in outline format to maximize the usefulness and convenience of this... |
 |
The BMT Data Book by Reinhold Munker (Author), Hillard M. Lazarus (Author), Kerry Atkinson (Author) The BMT Data Book is an essential guide to the data, outcome studies and complex decision-making processes involved in blood and marrow stem cell transplantation. Organized according to types of diseases and procedures, it contains more than hundred tables, figures and algorithms that reflect up-to-date research and give guidance on the choices between stem cell versus bone marrow transplantation, autologous versus allogeneic transplantation, and conventional versus experimental treatments. This new edition summarizes research of the last 5 years and gives mature data for all established indications, such as acute myeloid leukemia, myelodysplastic syndromes, Hodgkin's and Non-Hodgkin's lymphomas. In addition, controversies and new indications - like renal cell cancer and autoimmune... |
 |
Bone Marrow Transplantation (Vademecum) by Richard K. Burt (Editor) The unique, compact, pocket-sized format of Bone Marrow Transplantation makes this text a practical. ready-reference for house officers, fellows, nurses and pharmacists on the bone marrow transplant unit. Topics covered include: Diseases requiring bone marrow transplants, such as multiple myeloma, lymphomas, pediatric malignancies and adult solid tumors; indications, complications, drug doses and approaches to clinical management problems; unrelated donors, marrow processing, engraftment relapse and general patient care; and the requirements for maintaining a bone marrow transplant unit. |
 |
Practical Hematopoietic Stem Cell Transplantation by Andrew J. Cant (Editor), Angela Galloway (Editor), Graham Jackson (Editor) Practical Hematopoietic Stem Cell Transplantation is the only comprehensive yet practical guide to the total care of the transplant patient. It provides a ready source of reference to help health care professionals involved in the management of patients requiring bone marrow and stem cell transplantations – covering many of the infections and complications that may arise. An essential, practical manual for all those working in the field of bone marrow and stem cell transplantation Whether you are an established... |
 |
False Hope: Bone Marrow Transplantation for Breast Cancer by Richard A. Rettig (Author), Peter D. Jacobson (Author), Cynthia M. Farquhar M.D. (Author), Wade M. Aubry M.D. (Author) In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story's implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones. It details how the factors that... |
 |
The BMT Data Book: A Manual for Bone Marrow and Blood Stem Cell Transplantation by Kerry Atkinson (Author) The BMT Data Book serves as a reference to aid the often complex decision-making process confronting today's clinician. Organized according to disorder, hundreds of tables, lists, and figures summarize data necessary to understand transplantation therapy for leukemia, lymphoma, aplastic anemia, breast cancer, testicular cancer, and other malignancies. For each, clinical outcomes are compared between transplant and nontransplant therapies. Additional sections outline procedures, cytotoxic drug regimes, basic science, and laboratory medicine. A concise, comprehensive manual, The BMT Data Book will provide a unique reference tool for all clinicians involved in bone marrow or blood cell transplantation. It may also be used as a companion to Clinical Bone Marrow Transplantation, 1994,... |
 |
Handbook of Bone Marrow Transplantation by Jacob M Rowe (Author), Angelo M Carella (Author), Hillard M Lazarus (Author) (Martin Dunitz) Rambam Medical Center and Technion, Haifa, Israel. Presents an overview of a selection of topics relating to issues in bone marrow transplantation. Includes a discussion of the advances being made in stem cell selection devices. For transplantation specialists and researchers. |
|
Bone Marrow Transplantation Across Major Genetic Barriers by Yair Reisner (Editor), Massimo F. Martelli (Editor) The importance of bone marrow transplantation for patients who do not have a matched sibling donor cannot be overestimated. This subject has always been in the public domain, accentuated by dramatic appeals, from time to time, to search for matched volunteer donors in the public at large. Unfortunately, the availability of such donors is limited, due to the remarkable genetic diversity of humans. Thus, although registries of such volunteers now include more than seven million individuals, we still face the problem of finding a matched donor for about 30 per cent of patients in need. To address this burning issue, extensive clinical and basic research is performed in leading institutes around the world. This book presents updated accounts of the different aspects of this research. The... | |
|
Bone Marrow Transplantation: Principles, Practice, and Nursing Insights (Jones and Barlett Series in Nursing) by Marie Bakitas Whedon (Editor) | |
 |
Bone Marrow Transplantation Toolkit - Comprehensive Medical Encyclopedia with Treatment Options, Clinical Data, and Practical Information (Two CD-ROM Set) by U.S. Government (Author) This up-to-date and comprehensive set of two CD-ROM discs provides a superb collection of official Federal government documents on the subject of bone marrow transplantation. Bone marrow is the spongy tissue inside some of your bones, such as your hip and thigh bones. It contains immature cells, called stem cells. The stem cells can develop into the red blood cells that carry oxygen through your body, the white blood cells that fight infections, and the platelets help with blood clotting. If there is a problem with your bone marrow, a transplant can give you healthy new marrow. You could need a transplant because of a disease, such as bone marrow diseases or cancers like leukemia or lymphoma. Or you might need one if a strong cancer treatment kills your healthy blood cells. For... |
| © 2009 BrightSurf.com |